On April 28, the Gay, Lesbian, Bisexual and Transgender Community Center of Baltimore and Central Maryland (GLCCB) hosted a town hall at the Waxter Center with 30 people in attendance to discuss the use of pre-exposure prophylaxis, or PrEP, to prevent HIV infection. PrEP is medicine taken daily by HIV-negative people who are at high risk of exposure to HIV, to prevent becoming infected with HIV.
Tenofovir-emtricitabine, or Truvada, manufactured by pharmaceutical company Gilead, is currently the only medication approved for use as PrEP. Truvada is also widely used as part of HIV treatment. At this time, daily pills are the only form of PrEP.
The panelists included Brian M. Palmer, D.O., M.P.H., of Gilead Sciences, Inc.; Dr. Patrick Ryscavage, of University of Maryland Medical Center; Dr. Renata Arrington-Sanders, of Johns Hopkins Hospital; and Deb Dunn of Chase Brexton Health Services.